Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Medical
EPIC: VAL
Latest Price: 0.65  (-8.45% Descending)
52-week High: 1.68
52-week Low: 0.29
Market Cap: 6.89M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
ValiRx
www.valirx.com

ValiRx Plc a biopharmaceutical company developing novel technologies with a focus on the epigenomic analysis and treatment of cancer, but the technologies can be applied to other conditions, such as neurology and inflammatory diseases. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running its project portfolio to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest. The flagship product lines Val101 and val201 are based on ValiRx’s patented GeneICE technology and technology licence from Cancer research UK.  

Full ValiRx profile here
Pdf

ValiRx announces funding and partnership agreement

9th Mar 2010, 4:27 pm

ValiRx PLC (AIM: VAL) said is has entered into a funding and commercial partnership agreement with the Laboratory of Government Chemistry (LGC) and Cambridge based drug developer Horizon Discovery. This partnership provides funding for the development of ValiRx's Hypergenomics technology into new gene activity based diagnostics and screening products. Financial details were not disclosed.

The partners are the end users of such tests and potential long term customers; this provides further product distribution networks for the technology. ValiRx has now completed a pilot development study and the goal of the agreement is to formulate new commercial products in the service and testing arena.

The company said the market potential is considerable for a method that offers whole genome screening. The cancer diagnostics market is predicted to be around US$6 billion in 2010 with the global epigenetic market estimated to be US$1.7 billion and growing 60 percent by 2012.

ValiRx has worldwide exclusive rights for the Hypergenomics technology and will retain the commercialisation rights for future products that arise under this agreement.

Successful tests should enable a variety of products centered on epigenetic mapping to be produced and ValiRx will develop service and product offerings focused on cancer and stem cell diagnostics and monitoring.

The principal applications will be the selection of optimal therapy regimes for patients, a key issue for pharmaceutical companies when conducting clinical trials and for follow on studies for companion diagnostics for approved drugs. Development of companion diagnostics is increasingly essential for the registration of new therapeutic products providing a much needed boost to pharma revenues.

The partners have wide contact networks within the pharmaceutical industry and it is anticipated that the tests will be marketed to these existing networks as well as to the wider pharma/biotech industry, ValiRx said.

As previously announced, the company continues to progress its epigenomic therapeutic approach with its GeneICE Eurostars consortium and has now reached the milestones associated with the third quarter of this programme.

LGC was founded in 1996 following the privatisation of the Laboratory of the Government Chemist, today LGC is owned by the management and staff and funds managed by the investment group LGV Capital. LGC retains its statutory role as Government Chemist, acting as the referee in cases where there is a dispute over analytical results or their interpretation.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.